Cargando…

PB1940: REAL-LIFE EXPERIENCE OF THE IMMUNE RECONSTITUTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND SMALL LYMPHOCYTIC LYMPHOMA TREATED WITH IBRUTINIB.

Detalles Bibliográficos
Autores principales:	Pérez, Belén Olivares, Nájar, Francisco José Jiménez, Pérez, Clara Aparicio, Teomiro, Ana Camila González, Reyes, Alfredo Pacheco, Fernández de la Mata, Margarita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430387/ http://dx.doi.org/10.1097/01.HS9.0000974576.60012.47

Ejemplares similares

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

PB1908: NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY
por: Jorge, Joana, et al.
Publicado: (2023)

PB1921: IS CHEMOIMMUNOTHERAPY (CIT) HISTORY IN THE FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA?
por: Parbutt, Catherine, et al.
Publicado: (2023)

PB1879: OVERALL SURVIVAL OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB IN ALBANIA (2018-2022)
por: Calliku, E., et al.
Publicado: (2022)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
por: Jorge, Joana, et al.
Publicado: (2023)

PB1854: NEXT GENERATION SEQUENCING APPROACHES IN CHRONIC LYMPHOCYTIC LEUKAEMIA: FINDINGS FROM EXTERNAL QUALITY ASSESSMENT
por: Cartwright, A., et al.
Publicado: (2022)

PB1932: RETROSPECTIVE STUDY OF BURDEN OF INFECTION IN PATIENTS WITH AND WITHOUT SECONDARY IMMUNODEFICIENCY DISEASE FOLLOWING DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Davids, Matthew, et al.
Publicado: (2023)

PB1944: INDIVIDUALS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA SHOW IMPAIRED HUMORAL BUT NORMAL CELLULAR IMMUNE RESPONSES AFTER RECEIVING A COMPLETE VACCINATION SCHEDULE AGAINST SARS-COV-2
por: Sánchez-Menéndez, Clara, et al.
Publicado: (2023)

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA
por: Ilhan, O., et al.
Publicado: (2022)

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
por: Holmes, Katie B., et al.
Publicado: (2019)

PB1872: ANTIBODY RESPONSES AFTER COVID-19 VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA, EITHER TREATED OR NAÏVE. A MONOCENTRIC EXPERIENCE.
por: Innocenti, I., et al.
Publicado: (2022)

PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL-DEFINED REGION.
por: Andersson, Maria, et al.
Publicado: (2023)

PB2490: NEUTROPHIL TO LYMPHOCYTE RATIO AND PLATELET TO LYMPHOCYTE RATIO IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MONOCENTRIC STUDY
por: Tounsi, Haifa, et al.
Publicado: (2023)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Barrientos, J. C., et al.
Publicado: (2022)

PB1940: ACQUIRED APLASTIC ANEMIA: THE CHALLENGE OF TREATMENT IN MEXICO. SINGLE HEMATOLOGY CENTER EXPERIENCE
por: Guajardo Leal, M. L., et al.
Publicado: (2022)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

PB1858: INFLUENCE OF INFLAMMATION ON ANGIOGENIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Mitrović Ajtić, O., et al.
Publicado: (2022)

PB2296: THE PROGNOSTIC ROLE OF NEUTROPHIL TO LYMPHOCYTE RATIO AND PLATELET TO LYMPHOCYTE RATIO IN COVID-19 PATIENTS: A MONOCENTRIC STUDY
por: Boufrikha, W., et al.
Publicado: (2022)

PB1820: THE EFFECT OF CONVENTIONAL CHEMOTHERAPY AFTER EXITING QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA
por: Láinez-González, Daniel, et al.
Publicado: (2023)

PB1744: THE RATIO OF ABSOLUTE LYMPHOCYTE COUNT AT INTERIM OF THERAPY TO ABSOLUTE LYMPHOCYTE COUNT AT DIAGNOSIS PREDICTS SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA
por: Faiza, Talbi, et al.
Publicado: (2023)

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Klodzinskiy, A., et al.
Publicado: (2022)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PB2392: MRNA IDENTIFICATION OF TIGIT IN PERITUMORAL LYMPHOCYTES IN CLASSICAL HODGKIN DISEASE
por: Annibali, Ombretta, et al.
Publicado: (2023)

PB1941: MIND-BODY INTERVENTION PROLONGS LYMPHOCYTE DOUBLING TIME AND TREATMENT-FREE SURVIVAL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Shapira, Shirley, et al.
Publicado: (2023)

PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
por: Qerama, Shaqir, et al.
Publicado: (2023)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB1870: COVID - 19 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: HOSPITAL MORALITY PREDICTORS
por: Kochneva, O., et al.
Publicado: (2022)

PB2207: NEUTROPHIL–TO-LYMPHOCYTE RATIO IS AN EARLY SCREENING TOOL FOR DIAGNOSIS OF POLYCYTHEMIA VERA
por: Yoon, Seug Yun, et al.
Publicado: (2023)

PB2461: CONDITIONING REGIMEN AND SUBPOPULATION COMPOSITION OF AUTOGRAFT LYMPHOCYTES IN PATIENTS WITH MULTIPLE MYELOMA
por: Kostroma, Ivan, et al.
Publicado: (2023)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
por: Jones, Jeffrey A., et al.
Publicado: (2017)

PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS
por: Buske, C., et al.
Publicado: (2022)

PB1873: EFFECTS OF LENALIDOMIDE MAINTENANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A TRIAL-SEQUENTIAL ANALYSIS
por: Lee, C.-H., et al.
Publicado: (2022)

PB2253: NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AS A PREDICTOR OF SEVERE COVID-19 ON ADMISSION
por: Ababou, M., et al.
Publicado: (2022)

PB1855: LACK OF MUTATIONS IN TNFRSF13B (TACI) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Giannakoulas, N., et al.
Publicado: (2022)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

PB1920: TARGETING THE TUMOR MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING LEUKOTRIENE INHIBITORS
por: Sadeghi, Laia, et al.
Publicado: (2023)

PB1915: THE MULTI-FACETED ROLE OF ORAL AND GUT MICROBIOME IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Paziewska, Magdalena, et al.
Publicado: (2023)

PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Karan-Đurašević, Teodora, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g2bdqt2fi0hvc6fmal5laldk6f